Shares of International Stem Cell Corp. (OTCMKTS:ISCO – Get Free Report) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.16 and traded as high as $0.1654. International Stem Cell shares last traded at $0.1654, with a volume of 1,960 shares changing hands.
International Stem Cell Stock Up 3.4%
The company has a market capitalization of $1.32 million, a PE ratio of -2.76 and a beta of -0.01. The stock has a 50-day moving average of $0.17 and a 200 day moving average of $0.16.
International Stem Cell (OTCMKTS:ISCO – Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.03) EPS for the quarter. The company had revenue of $2.32 million during the quarter.
About International Stem Cell
International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.
In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.
Featured Stories
- Five stocks we like better than International Stem Cell
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
- MarketBeat Week in Review – 07/06 – 07/10
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.
